Search Results

By L. Elizabeth Budde, MD, PhD, Samer K. Khaled, MD, and Stephen J. Forman, MD, FACP  / December 15, 2014

Racing Against Acute Lymphoblastic Leukemia: CTL019 Is a Fast CAR With Sustained Endurance

The long-term outcome for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor, with 5-year overall survival from first relapse being only approximately 10%.1,2 Patients with disease relapse following allogeneic transplant have the worse prognosis and are typically...